Ipsen S.A. (IPN.PA) Stock Analysis & Winston Score

Ipsen is a French pharmaceutical company that makes specialty medicines for serious diseases. Its main focus areas are cancer (oncology), rare diseases, and neuroscience. Key products include Somatuline for certain tumors, Decapeptyl for prostate cancer, and Dysport, a botulinum toxin used to treat muscle disorders. Hospitals, specialist doctors, and patients with rare or complex conditions are its primary customers. Ipsen earns money by selling prescription drugs, mostly to healthcare systems and insurers across more than 115 countries. It is headquartered in Paris and generates roughly €3 billion in annual revenue, with a strong gross margin above 70% reflecting the pricing power typical of specialty pharmaceuticals. Its moat comes from patented drugs targeting niche diseases where few alternatives exist. The key growth driver is expanding its oncology pipeline, including newer assets like palovarotene for a rare bone disease, but the main risk is patent expiration on older products, which could allow cheaper generic competition to erode revenue.